MedTrace Logo

Safety and Pharmacokinetics Study in Healthy Japanese Volunteers

NCT05032560 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-01-26

No results posted yet for this study

Summary

The study consists of Part A, a randomized double-blind, single-ascending-dose study, and Part B, a randomized, double-blind, semi-sequential, escalating multiple-dose study, in healthy Japanese volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

ABX464

Drug: ABX464 ABX464 is a new anti-inflammatory drug

DRUG

Placebo

Drug: Matching Placebo placebo matching with ABX464

Sponsors & Collaborators

  • Abivax S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-27
Primary Completion
2022-02-18
Completion
2022-02-18

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05032560 on ClinicalTrials.gov